Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, February 21, 2023
[ Tue, Feb 21st 2023
] - WOPRAI
[ Tue, Feb 21st 2023
] - WOPRAI
[ Tue, Feb 21st 2023
] - WOPRAI
[ Tue, Feb 21st 2023
] - WOPRAI
[ Tue, Feb 21st 2023
] - WOPRAI
[ Tue, Feb 21st 2023
] - WOPRAI
[ Tue, Feb 21st 2023
] - WOPRAI
[ Tue, Feb 21st 2023
] - WOPRAI
[ Tue, Feb 21st 2023
] - WOPRAI
[ Tue, Feb 21st 2023
] - WOPRAI
[ Tue, Feb 21st 2023
] - WOPRAI
[ Tue, Feb 21st 2023
] - WOPRAI
[ Tue, Feb 21st 2023
] - WOPRAI
[ Tue, Feb 21st 2023
] - WOPRAI
[ Tue, Feb 21st 2023
] - WOPRAI
[ Tue, Feb 21st 2023
] - WOPRAI
[ Tue, Feb 21st 2023
] - WOPRAI
[ Tue, Feb 21st 2023
] - WOPRAI
[ Tue, Feb 21st 2023
] - WOPRAI
[ Tue, Feb 21st 2023
] - WOPRAI
[ Tue, Feb 21st 2023
] - WOPRAI
[ Tue, Feb 21st 2023
] - WOPRAI
[ Tue, Feb 21st 2023
] - WOPRAI
[ Tue, Feb 21st 2023
] - WOPRAI
[ Tue, Feb 21st 2023
] - WOPRAI
[ Tue, Feb 21st 2023
] - WOPRAI
[ Tue, Feb 21st 2023
] - WOPRAI
[ Tue, Feb 21st 2023
] - WOPRAI
[ Tue, Feb 21st 2023
] - WOPRAI
Joseph Pantginis Reiterated (ATNM) at Strong Buy and Held Target at $53 on, Feb 21st, 2023
Joseph Pantginis of HC Wainwright & Co., Reiterated "Actinium Pharmaceuticals, Inc." (ATNM) at Strong Buy and Held Target at $53 on, Feb 21st, 2023.
Joseph has made no other calls on ATNM in the last 4 months.
There is 1 other peer that has a rating on ATNM. Out of the 1 peers that are also analyzing ATNM, 0 agree with Joseph's Rating of Hold.
This is the rating of the analyst that currently disagrees with Joseph
- Yuan Zhi of "B. Riley Securities" Maintained at Strong Buy with Increased Target to $18 on, Monday, October 31st, 2022
